Ratings Pacific Biosciences of California, Inc. Deutsche Boerse AG

Equities

P09

US69404D1081

Market Closed - Deutsche Boerse AG Other stock markets 07:06:28 20/05/2024 BST			5-day change	1st Jan Change
1.8 ^EUR	-7.71%		-1.52%	-79.67%

05-15	Pacific Biosciences, Ambry Genetics Selected to Sequence up to 7,000 Human Genomes	MT
05-15	Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 61% by 2026.
The company's share price in relation to its net book value makes it look relatively cheap.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.	-79.67%	550M	-
THERMO FISHER SCIENTIFIC	+11.91%	227B	B
DANAHER CORPORATION	+15.46%	197B	B-
INTUITIVE SURGICAL, INC.	+18.58%	141B	B-
BOSTON SCIENTIFIC CORPORATION	+30.36%	110B	A-
SIEMENS HEALTHINEERS AG	+0.65%	64.15B	A-
EDWARDS LIFESCIENCES CORPORATION	+17.74%	53.72B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+5.82%	51.75B	B+
AGILENT TECHNOLOGIES, INC.	+11.23%	45.2B	A
GE HEALTHCARE TECHNOLOGIES INC.	+5.73%	37.37B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes